For research use only.

Catalog No.S2907 Synonyms: S-7701,AMR-69

29 publications

Pirfenidone Chemical Structure

CAS No. 53179-13-8

Pirfenidone (S-7701, AMR-69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 90 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pirfenidone has been cited by 29 publications

Purity & Quality Control

Choose Selective TGF-beta/Smad Inhibitors

Biological Activity

Description Pirfenidone (S-7701, AMR-69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.
TGF-β [2]
(Cell-free assay)
In vitro

Pirfenidone (< 300 μg/mL) suppresses the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism in RAW264.7 cells, which is independent of activation of the mitogen-activated protain kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK). [1] Pirfenidone (< 10 mM) leads to reduced glioma cell density in concentration-dependent manner in LN-18, T98G, LNT-229 and LN-308 cell lines. Pirfenidone (< 5 mM) reduces TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. Pirfenidone (< 8.3 mM) inhibits the activity of recombinant furin and downregulates the expression of MMP-11 in a dose-dependent manner in LN-308 cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HFL1 cells MmTYSpVv[3Srb36gZZN{[Xl? MWq0PEBp MnnJRY51cW[rYoLveIlkKGGldHn2bZR6KGmwIFjGUFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuO|Eh|ryPLh?= NXTneXh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PVY4ODdpPkK2PFk3PzB5PD;hQi=>
LNCaP M3u2bGNmdGxiZ4Lve5RpKGG|c3H5 MVuwMEAxNjFuIECuN{Bu\y:vbB?= NXPYRlJrOyCmYYnz MmrnVGZFKHS{ZXH0cYVvfCC|aXfubYZq[2GwdHz5JJN2eHC{ZYPz[YQhfGinIHfyc5d1cCCxZjDj[YxteyCjdDCwMlMhdWdxbXy= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ{MUG3OUc,OzB4MkGxO|U9N2F-
PC-3 M2PZS2NmdGxiZ4Lve5RpKGG|c3H5 MXWwMEAxNjFuIECuN{Bu\y:vbB?= NWL2UZdYOyCmYYnz NIrh[pNRTkRidILlZZRu\W62IIPp[45q\mmlYX70cJkhe3WycILld5Nm\CC2aHWg[5Jwf3SqIH;mJINmdGy|IHH0JFAvOyCvZz;tcC=> MofCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB4MkGxO|UoRjNyNkKxNVc2RC:jPh?=
E9 NX;Z[nRiS2WubDDndo94fGhiYYPzZZk> M1j1VFAtKDBwMTygNE4{KG2pL33s NYnDW4pMOyCmYYnz M4HI[3BHTCC2cnXheI1mdnRic3nncolncWOjboTsfUB{fXCycnXzd4VlKHSqZTDndo94fGhib3[gZ4VtdHNiYYSgNE4{KG2pL33s MlzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB4MkGxO|UoRjNyNkKxNVc2RC:jPh?=
F10 NHTMXFFE\WyuIHfyc5d1cCCjc4PhfS=> MoO1NEwhOC5zLDCwMlMhdWdxbXy= MU[zJIRigXN? NVr6WopxWE[GIITy[YF1dWWwdDDzbYdvcW[rY3HueIx6KHO3cIDy[ZN{\WRidHjlJIdzd3e2aDDv[kBk\WyuczDheEAxNjNibXevcYw> Mo\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB4MkGxO|UoRjNyNkKxNVc2RC:jPh?=
AIDL M3:3O2NmdGxiZ4Lve5RpKGG|c3H5 M1fkfVAtKDBwMTygNE4{KG2pL33s NUG0TJhFOyCmYYnz M3XuWHBHTCC2cnXheI1mdnRic3nncolncWOjboTsfUB{fXCycnXzd4VlKHSqZTDndo94fGhib3[gZ4VtdHNiYYSgNE4{KG2pL33s MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ{MUG3OUc,OzB4MkGxO|U9N2F-
human intestinal fibroblasts (HIFs) MU\GeY5kfGmxbjDhd5NigQ>? M4m2RlEhcA>? NHK2VXBRTkRiaX7obYJqfHNiSFnGd{BlcW[oZYLlcpRq[XSrb36gZY5lKHSqZTDjc4xt[WenbjDk[ZBwe2m2aX;uJIlv\HWlZXSgZpkhXEeILd8yNU4> NFXGVYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG1Nlg1QCd-M{CxOVI5PDh:L3G+

... Click to View More Cell Line Experimental Data

Methods Test Index PMID

PubMed: 22132230     

Effects of 1.0 or 1.5 mg/ml pirfenidone on α-SMA expression and morphological changes of CFs (Cardiac fibroblasts) were determined by immunofluorescence staining with anti-α-SMA antibody. Scale bar = 50.0 µm. 

SMAD4 / SMAD2 / SMAD3 ; 

PubMed: 23437252     

After stimulated by 12.5 ng/ml TGF-β2 for 24 hours, the staining of nuclei SMAD4 (green) enhanced when that of SMAD4 in the cytoplasm were weakened, and SMAD2/3 proteins (red) were assembled on the nuclear membrane and some of them entered the nuclei. Expression of nuclei SMAD2/3 and SMAD4 were depressed after treatment with 0.5 mg/ml pirfenidone. The nuclei stained by DAPI (blue). Magnification, ×1000.

F-actin / β-catenin / Vimentin ; 

PubMed: 29325547     

Immunofluorescence staining showed that treatment with SB or PFD increased E-cadherin levels, decreased vimentin and nuclear β-catenin distribution in MCF-7 and MDA-MB-231 cells. CAFs promoted F-actin polymerization and stability in cancer cells, whereas treatment with SB or PFD impaired the formation of stress fibers. Scale bar: 15 μm

22132230 23437252 29325547
In vivo Pirfenidone (250 mg/kg) potently inhibits the production of the proinflammatory cytokines, TNF-alpha, interferon-gamma, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10, in mice. [1] Pirfenidone (250 mg/kg/day) ameliorates cyclosporine-induced fibrosis by about 50% and decreases TGF-beta1 protein expression by 80% in Sprague-Dawley rats receiving a low-salt diet. [3] Pirfenidone (400 mg/kg/day) inhibits heat shock protein 47-positive cells and myofibroblasts, the principal cells responsible for the accumulation and deposition of extracellular matrix seen in pulmonary fibrosis in ICR mice intravenously injected with bleomycin. [4] Pirfenidone (0.5%, liquid diet) treatment reduces the degree of liver injury in rats, as determined by alanine aminotransferase values and necro-inflammatory score, which is associated with reduced hepatic stellate cells proliferation and collagen deposition. Pirfenidone (0.5%, liquid diet) administration downregulates dimethylnitrosamine induced transcripts levels of procollagen alpha1(I), TIMP-1 and MMP-2 by 50-60% in rats, and this is associated with a 70% reduction in collagen deposition. [5]


Animal Research:[3]
- Collapse
  • Animal Models: Sprague-Dawley rats receiving a low-salt diet
  • Dosages: 250 mg/kg
  • Administration: oral diet
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 37 mg/mL (199.76 mM)
Ethanol 37 mg/mL (199.76 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 185.22


CAS No. 53179-13-8
Storage powder
in solvent
Synonyms S-7701,AMR-69
Smiles CC1=CN(C(=O)C=C1)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04631354 Completed Drug: Radio-labelled S-770108|Device: S-770108 Inhaler A1 Healthy Volunteer Shionogi|Shionogi Inc. November 9 2020 Phase 1
NCT04607928 Recruiting Drug: Pirfenidone|Drug: Placebo Fibrotic Pulmonary Sequelae Post-COVID19 Infection Institut d''Investigació Biomèdica de Bellvitge August 1 2020 Phase 2
NCT03692481 Recruiting Radiation: 18FDG-PET scan Idiopathic Pulmonary Fibrosis Assistance Publique - Hôpitaux de Paris February 4 2020 Not Applicable
NCT04126538 Recruiting Drug: pirfenidone capsule Renal Insufficiency Beijing Continent Pharmaceutical Co Ltd. August 27 2019 Phase 1
NCT03981094 Completed Drug: BMS-986278|Drug: Pirfenidone Idiopathic Pulmonary Fibrosis (IPF) Bristol-Myers Squibb May 10 2019 Phase 1
NCT03958071 Completed Drug: Nintedanib|Drug: Pirfenidone|Other: Untreated Cohort Idiopathic Pulmonary Fibrosis Boehringer Ingelheim February 1 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'd like to know how to use your 50mg dose pirfenidone to make a solution for intraperitoneal injection in a mouse. Could you give me some advice?

  • Answer:

    For I.P. injection, S2907 Pirfenidone can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water.

TGF-beta/Smad Signaling Pathway Map

Related TGF-beta/Smad Products

Tags: buy Pirfenidone | Pirfenidone supplier | purchase Pirfenidone | Pirfenidone cost | Pirfenidone manufacturer | order Pirfenidone | Pirfenidone distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID